Sat Kartar Life Announces Healthcare Expansion, Targets ₹ 500 Crore Revenue by FY28

Sat Kartar Life Announces Healthcare Expansion, Targets ₹ 500 Crore Revenue by FY28​

Sat Kartar Life Limited, formerly Sat Kartar Shopping Ltd, is undergoing a strategic transformation into a comprehensive Ayurveda healthcare enterprise. The company is expanding its footprint by launching specialized clinical facilities and leveraging technology to build a patient-centric ecosystem, while projecting robust growth driven by its dual-engine model.

The company has established an integrated approach by combining traditional Ayurvedic knowledge with modern clinical science. This commitment is underlined by the launch of the first Sat Kartar Ayurveda Hospital, a 30-bed facility in Delhi, operational as of March 5, 2026. This hospital aims to serve a dense urban population, capitalizing on the growing preference for alternative and preventive healthcare.

The hospital model is designed to be capital-efficient, boasting a setup cost of ₹ 7-8 lakh per bed. The facilities, built across 13,500 Sq. Feet, feature consultation, therapy, recovery, and procedure rooms. Operational efficiency is key, with the average revenue projected at ₹ 10,000 per bed per day, supplemented by additional revenue from in-house manufactured medicines.

Strategic Growth Initiatives​

Sat Kartar Life Limited is building its scale through strategic collaborations and capital infusion. The company entered into a 3-year strategic Memorandum of Understanding (MOU) in April 2026 with Jeena Sikho Lifecare Limited. This partnership aims to expand Ayurveda healthcare delivery by jointly utilizing capabilities in distribution, product development, and patient outreach, thereby strengthening organized Ayurveda healthcare across India.

The company recently secured capital through a preferential issue of ₹ 48.58 Cr, which included the issuance of 50,400 equity shares and 27.74 lakh convertible warrants. The fundraise saw participation from 15 investors, led by LIGHTHOUSE CANTON, alongside notable HNIs and family offices. Additionally, Sat Kartar Life Ltd acquired an additional 24% stake in Plantomed Neutraceuticals, making it a wholly owned subsidiary.

Operationally, the company is increasing its reach through the commissioning of four new call centres in Tamil Nadu, Karnataka, and NCR. Furthermore, the integration of Artificial Intelligence (AI) initiatives is directly linked to measurable outcomes, including improved conversion rates and reduced customer acquisition cost (CAC).

Financial Performance and Targets​

The company reported strong growth in its financial performance. Analyzing the consolidated Profit & Loss statement data (in ₹ Crores), the results show significant year-over-year growth:


The balance sheet data (in ₹ Crores) reflects the company's growing assets:

Future Growth Trajectory​

The company maintains a clear growth roadmap centered on expanding capacity and increasing revenue visibility. Management is confident in achieving a revenue milestone of ₹ 500 Crore by FY28.

Key targets include:

• Hospital Capacity Scale-Up: Increasing capacity from 30 beds in FY26 to an estimated 300 beds by FY27E, and further scaling to 1000 beds by FY28E.
• Revenue Contribution: Hospitals are expected to contribute ₹ 100+ Crore by FY28, emerging as a major growth driver.
• Nutraceuticals: Plantomed Neutraceuticals, now a wholly owned subsidiary, is positioned for scale-up, targeting ₹ 40-60 Crore by FY28 with its affordable, high-retention portfolio focused on diabetes care.

The growth strategy emphasizes horizontal expansion into yoga therapy and integrated wellness clinics, alongside hyper-personalized wellness using AI-driven recommendations. The company also plans its entry into US markets through subsidiaries to capture global demand for Ayurvedic products.

SATKARTAR Stock Price Movement​

Shares of Sat Kartar Life Limited are slipping by 0.60% in live trading, currently registering at ₹200 as of 10:18 AM. The stock is seeing active interest, trading today on a volume of 44,000 shares, moving ₹1.20 down from its previous close.